As tumor cells, including AML cells, overexpress the NK-1R, the use of NK-1R antagonists could be an excellent common antitumor strategy against AML, since it is a heterogeneous disease that is difficult to treat due to the characteristics of the cytogenetic subtypes and the potentially-differing morphological and clinical properties from person to person. Here, TACR1 is linked to neoplasm.